What question did this study set out to answer?

To evaluate the efficacy and safety of combining transarterial chemoembolization (TACE) with camrelizumab and apatinib compared to TACE monotherapy in patients with unresectable hepatocellular carcinoma.

June 22, 2026Bratislavské lekárske listy/Bratislava medical journalOpen Access

The Efficiency and Safety of Tace Combined with Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of combining transarterial chemoembolization (TACE) with camrelizumab and apatinib compared to TACE monotherapy in patients with unresectable hepatocellular carcinoma.
Retrospective analysis of 104 patients with unresectable hepatocellular carcinoma treated between October 2020 and October 2023.
Patients were allocated to either TACE monotherapy (n = 53) or TACE combined with camrelizumab and apatinib (n = 39).
Tumor response was assessed using mRECIST criteria, survival evaluated by Kaplan–Meier methods, and adverse events tracked.
The objective response rate was significantly higher in the combination group compared to TACE monotherapy (64.1% vs. 37.7%, P = 0.012), with disease control rates of 76.9% vs. 77.4%.
Median progression-free survival was significantly prolonged with combination therapy compared to monotherapy (9.0 vs. 6.0 months; HR = 0.60, 95% CI 0.383–0.941; P = 0.019).
Median overall survival showed a non-significant trend favoring combination therapy (16.0 months vs. not reached; HR = 0.548, 95% CI 0.298–1.006; P = 0.06), with mostly Grade 1–2 adverse events and one case of hyperprogressive disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study demonstrates improved tumor response and progression-free survival in advanced hepatocellular carcinoma, indicating clinical benefit for combined triple therapy.

Cite This Study

Kong et al. (2026) studied this question.

synapsesocial.com/papers/6a986455197de90645e341d4 https://doi.org/10.1007/s44411-026-00717-9

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study demonstrates improved tumor response and progression-free survival in advanced hepatocellular carcinoma, indicating clinical benefit for combined triple therapy.

The Efficiency and Safety of Tace Combined with Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

Key Points

Discussion

Implication

Cite This Study

The Efficiency and Safety of Tace Combined with Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading